Modality
mAb
MOA
CDK4/6i
Target
AHR
Pathway
Wnt
SCLC
Development Pipeline
Preclinical
Jan 2023
→ Nov 2029
PreclinicalCurrent
NCT08252082
1,915 pts·SCLC
2023-01→2029-11·Completed
1,915 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-183.6y awayInterim· SCLC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2029-11-18 · 3.6y away
SCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08252082 | Preclinical | SCLC | Completed | 1915 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |